ELITE PHARMACEUTICALS INC /NV/ Quarterly Accounts Receivable, after Allowance for Credit Loss, Current in USD from Q1 2011 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.
Summary
Elite Pharmaceuticals Inc /Nv/ quarterly Accounts Receivable, after Allowance for Credit Loss, Current history and growth rate from Q1 2011 to Q3 2024.
  • Elite Pharmaceuticals Inc /Nv/ Accounts Receivable, after Allowance for Credit Loss, Current for the quarter ending September 30, 2024 was $21.4M, a 104% increase year-over-year.
Accounts Receivable, after Allowance for Credit Loss, Current, Quarterly (USD)
Accounts Receivable, after Allowance for Credit Loss, Current, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date Report Filed
Q3 2024 $21.4M +$10.9M +104% Sep 30, 2024 10-Q 2024-11-14
Q2 2024 $20.5M +$14.3M +230% Jun 30, 2024 10-Q 2024-08-14
Q1 2024 $19.5M +$16.4M +529% Mar 31, 2024 10-Q 2024-11-14
Q4 2023 $16M +$10.5M +189% Dec 31, 2023 10-Q 2024-02-14
Q3 2023 $10.5M +$6.27M +148% Sep 30, 2023 10-Q 2023-11-14
Q2 2023 $6.2M +$2.24M +56.4% Jun 30, 2023 10-Q 2023-08-14
Q1 2023 $3.09M +$36.6K +1.2% Mar 31, 2023 10-K 2024-07-01
Q4 2022 $5.55M +$2.88M +108% Dec 31, 2022 10-Q 2023-02-14
Q3 2022 $4.23M -$443K -9.48% Sep 30, 2022 10-Q 2022-11-14
Q2 2022 $3.97M +$587K +17.4% Jun 30, 2022 10-Q 2022-08-15
Q1 2022 $3.06M -$438K -12.5% Mar 31, 2022 10-K 2023-06-29
Q4 2021 $2.66M -$635K -19.3% Dec 31, 2021 10-Q 2022-02-14
Q3 2021 $4.67M +$596K +14.6% Sep 30, 2021 10-Q 2021-11-15
Q2 2021 $3.38M -$992K -22.7% Jun 30, 2021 10-Q 2021-08-16
Q1 2021 $3.5M -$610K -14.9% Mar 31, 2021 10-K 2022-06-29
Q4 2020 $3.3M +$731K +28.5% Dec 31, 2020 10-Q 2021-02-16
Q3 2020 $4.08M +$2.05M +101% Sep 30, 2020 10-Q 2020-11-16
Q2 2020 $4.37M +$3.37M +338% Jun 30, 2020 10-Q 2020-08-14
Q1 2020 $4.11M +$2.79M +211% Mar 31, 2020 10-K 2021-06-14
Q4 2019 $2.57M +$1.9M +288% Dec 31, 2019 10-Q 2020-02-10
Q3 2019 $2.03M +$1.01M +99.8% Sep 30, 2019 10-Q 2019-11-12
Q2 2019 $999K -$63.1K -5.94% Jun 30, 2019 10-Q 2019-08-09
Q1 2019 $1.32M +$646K +95.6% Mar 31, 2019 10-K 2020-06-30
Q4 2018 $660K -$501K -43.1% Dec 31, 2018 10-Q 2019-02-11
Q3 2018 $1.02M -$69.4K -6.4% Sep 30, 2018 10-Q 2018-11-09
Q2 2018 $1.06M +$341K +47.3% Jun 30, 2018 10-Q 2018-08-09
Q1 2018 $676K -$258K -27.6% Mar 31, 2018 10-K 2019-06-21
Q4 2017 $1.16M +$617K +113% Dec 31, 2017 10-Q 2018-02-09
Q3 2017 $1.09M -$60.2K -5.26% Sep 30, 2017 10-Q 2017-11-09
Q2 2017 $721K -$499K -40.9% Jun 30, 2017 10-Q 2017-08-09
Q1 2017 $934K -$596K -39% Mar 31, 2017 10-K 2018-06-14
Q4 2016 $545K -$202K -27.1% Dec 31, 2016 10-Q 2017-02-09
Q3 2016 $1.15M -$270K -19.1% Sep 30, 2016 10-Q 2016-11-09
Q2 2016 $1.22M +$172K +16.4% Jun 30, 2016 10-Q 2016-08-09
Q1 2016 $1.53M +$83.9K +5.8% Mar 31, 2016 10-K 2017-06-14
Q4 2015 $747K -$967K -56.4% Dec 31, 2015 10-Q 2016-02-09
Q3 2015 $1.42M +$318K +29% Sep 30, 2015 10-Q/A 2015-12-30
Q2 2015 $1.05M -$118K -10.1% Jun 30, 2015 10-Q/A 2015-12-30
Q1 2015 $1.45M +$714K +97.6% Mar 31, 2015 10-K 2016-06-15
Q4 2014 $1.71M +$690K +67.4% Dec 31, 2014 10-Q 2015-02-17
Q3 2014 $1.1M +$462K +72.6% Sep 30, 2014 10-Q 2014-11-14
Q2 2014 $1.17M +$668K +134% Jun 30, 2014 10-Q 2014-08-14
Q1 2014 $732K +$66.9K +10.1% Mar 31, 2014 10-K 2015-06-15
Q4 2013 $1.02M +$498K +94.6% Dec 31, 2013 10-Q 2014-02-14
Q3 2013 $636K +$73K +13% Sep 30, 2013 10-Q 2013-11-14
Q2 2013 $499K +$1.18K +0.24% Jun 30, 2013 10-Q 2013-08-14
Q1 2013 $665K +$268K +67.6% Mar 31, 2013 10-K 2014-06-30
Q4 2012 $526K +$43.1K +8.91% Dec 31, 2012 10-Q 2013-02-14
Q3 2012 $563K +$310K +123% Sep 30, 2012 10-Q 2012-11-14
Q2 2012 $498K -$15.6K -3.04% Jun 30, 2012 10-Q 2012-08-14
Q1 2012 $397K -$175K -30.6% Mar 31, 2012 10-K 2013-06-21
Q4 2011 $483K Dec 31, 2011 10-Q 2012-02-14
Q3 2011 $253K Sep 30, 2011 10-Q 2011-11-14
Q2 2011 $514K Jun 30, 2011 10-Q/A 2011-08-19
Q1 2011 $572K Mar 31, 2011 10-K 2012-06-29
* An asterisk sign (*) next to the value indicates that the value is likely invalid.